AI Engines For more Details: Perplexity Kagi Labs You
Obesity: Regular consumption of sugary sodas can contribute to weight gain and obesity due to their high sugar content and calorie density. Excessive calorie intake from sugary drinks, without compensating by reducing calorie intake from other sources or increasing physical activity, can lead to an imbalance in energy expenditure and storage, resulting in weight gain.
Type 2 Diabetes: Sugary sodas have been linked to an increased risk of type 2 diabetes. The high sugar content in these drinks can lead to elevated blood glucose levels, insulin resistance, and impaired insulin sensitivity over time. Chronic consumption of sugary sodas may contribute to the development of insulin resistance and diabetes, especially when combined with other risk factors such as obesity and sedentary lifestyle.
Cardiovascular Disease: Regular consumption of sugary sodas has been associated with an increased risk of cardiovascular diseases such as heart disease and stroke. The excessive intake of added sugars, particularly fructose, can raise blood triglyceride levels, promote inflammation, and contribute to the development of hypertension and atherosclerosis, all of which are risk factors for cardiovascular disease.
Dental Cavities: Sugary sodas can promote dental cavities and tooth decay due to their high sugar content and acidic nature. The combination of sugars and acids in these drinks can erode tooth enamel and create an environment conducive to bacterial growth, leading to cavities, tooth decay, and other dental problems.
Metabolic Syndrome: Consumption of sugary sodas has been linked to an increased risk of metabolic syndrome, a cluster of conditions including abdominal obesity, elevated blood pressure, high blood sugar, and abnormal lipid levels. Regular intake of sugary drinks can contribute to insulin resistance, dyslipidemia, and other metabolic abnormalities associated with metabolic syndrome.
Liver Disease: Excessive consumption of sugary sodas, particularly those containing high-fructose corn syrup, can contribute to non-alcoholic fatty liver disease (NAFLD) and other liver disorders. The liver metabolizes fructose differently from glucose, leading to increased fat accumulation in the liver, insulin resistance, and inflammation, which can contribute to the development of NAFLD and liver damage.
Kidney Disease: High intake of sugary sodas has been associated with an increased risk of kidney disease and kidney stones. The excessive sugar and phosphoric acid content in these drinks can contribute to the formation of kidney stones and impair kidney function over time.
Bone Health: Regular consumption of sugary sodas has been linked to reduced bone mineral density and an increased risk of osteoporosis, especially in children and adolescents. The phosphoric acid in sodas can interfere with calcium absorption and balance in the body, potentially leading to weaker bones and an increased risk of fractures.
| Rank | Probiotic | Impact |
|---|
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| Taxonomy | Rank | Effect | Citations | Notation |
|---|---|---|---|---|
| Segatella | genus | Increases | 👪 Source Study | |
| Streptococcus | genus | Increases | 👪 Source Study | |
| Segatella oulorum | species | Increases | 📓 Source Study | |
| Streptococcus parasanguinis | species | Increases | 📓 Source Study | |
| Streptococcus parasanguinis ATCC 15912 | strain | Increases | 👶 Source Study | |
| Streptococcus parasanguinis ATCC 903 | strain | Increases | 👶 Source Study | |
| Streptococcus parasanguinis CC87K | strain | Increases | 👶 Source Study | |
| Streptococcus parasanguinis DORA_23_24 | strain | Increases | 👶 Source Study | |
| Streptococcus parasanguinis F0405 | strain | Increases | 👶 Source Study | |
| Streptococcus parasanguinis F0449 | strain | Increases | 👶 Source Study | |
| Streptococcus parasanguinis FW213 | strain | Increases | 👶 Source Study | H01443 Viridans group streptococcal infection |
| Streptococcus parasanguinis SK236 | strain | Increases | 👶 Source Study |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Ankylosing spondylitis | 0.3 | -0.3 | |
| Antiphospholipid syndrome (APS) | 0.3 | -0.3 | |
| Atrial fibrillation | 0.3 | -0.3 | |
| Autism | 0.3 | 0.3 | 0 |
| Barrett esophagus cancer | 0.3 | 0.3 | |
| Carcinoma | 0.3 | -0.3 | |
| Celiac Disease | 0.3 | -0.3 | |
| Cerebral Palsy | 0.3 | -0.3 | |
| Chronic Fatigue Syndrome | 0.3 | 0.3 | 0 |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.9 | -0.9 | |
| Chronic Urticaria (Hives) | 0.3 | -0.3 | |
| Coagulation / Micro clot triggering bacteria | 0.3 | 0.3 | 0 |
| COVID-19 | 0.3 | 0.3 | 0 |
| deep vein thrombosis | 0.3 | 0.3 | |
| Depression | 0.3 | 0.9 | -2 |
| Dermatomyositis | 0.3 | -0.3 | |
| Eczema | 0.3 | 0.3 | |
| Endometriosis | 0.3 | -0.3 | |
| Epilepsy | 0.3 | -0.3 | |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.3 | 0.3 | |
| Glioblastoma | 0.3 | 0.3 | |
| Halitosis | 0.3 | 0.3 | |
| Hidradenitis Suppurativa | 0.3 | -0.3 | |
| hypertension (High Blood Pressure | 0.3 | 0.3 | 0 |
| Inflammatory Bowel Disease | 0.3 | -0.3 | |
| Insomnia | 0.3 | -0.3 | |
| Liver Cirrhosis | 0.3 | 0.3 | 0 |
| Long COVID | 0.3 | -0.3 | |
| ME/CFS with IBS | 0.3 | -0.3 | |
| ME/CFS without IBS | 0.3 | -0.3 | |
| Metabolic Syndrome | 0.3 | 0.3 | 0 |
| Mood Disorders | 0.3 | 0.9 | -2 |
| multiple chemical sensitivity [MCS] | 0.3 | -0.3 | |
| Multiple Sclerosis | 0.3 | 0.9 | -2 |
| Multiple system atrophy (MSA) | 0.6 | -0.6 | |
| Neuropathy (all types) | 0.3 | -0.3 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.3 | -0.3 | |
| Obesity | 0.3 | -0.3 | |
| obsessive-compulsive disorder | 0.3 | -0.3 | |
| Osteoarthritis | 0.3 | -0.3 | |
| pancreatic cancer | 0.3 | -0.3 | |
| Parkinson's Disease | 0.3 | 0.3 | 0 |
| Psoriasis | 0.3 | -0.3 | |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 0.3 | -0.3 | |
| Sjögren syndrome | 0.3 | -0.3 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.3 | -0.3 | |
| Systemic Lupus Erythematosus | 0.3 | -0.3 | |
| Type 1 Diabetes | 0.3 | 0.3 | |
| Type 2 Diabetes | 0.3 | 0.3 | 0 |
| Ulcerative colitis | 0.3 | -0.3 | |
| Unhealthy Ageing | 0.3 | -0.3 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.